output stringlengths 5 24.3k | instruction stringlengths 33 308 | system stringclasses 1 value |
|---|---|---|
1. Antineoplastic Agents [*adverse effects]; 2. Benzoates [*administration & dosage]; 3. Hydrazines [*administration & dosage]; 4. Neoplasms [drug therapy]; 5. Pyrazoles [*administration & dosage]; 6. Randomized Controlled Trials as Topic; 7. Receptors, Fc [*administration & dosage]; 8. Receptors, Thrombopoietin [*agonists]; 9. Recombinant Fusion Proteins [*administration & dosage]; 10. Thrombocytopenia [chemically induced, *drug therapy, mortality, *prevention & control]; 11. Thrombopoietin [*administration & dosage]; | Provide MESH terms for the study
Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in patients with solid tumours | You are a research assistant. Based on the question please provide appropriate answers |
1. Acute Disease; 2. Anemia, Sickle Cell [*complications]; 3. *Blood Transfusion; 4. *Conservative Treatment; 5. Recurrence; 6. Secondary Prevention; 7. *Splenectomy; 8. Splenic Diseases [surgery, *therapy]; | Provide MESH terms for the study
Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Gaucher Disease [*surgery]; 2. *Hematopoietic Stem Cell Transplantation [mortality]; | Provide MESH terms for the study
Hematopoietic stem cell transplantation for Gaucher disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Administration, Intravenous; 2. Apnea [etiology]; 3. Calcium [*administration & dosage, adverse effects, blood]; 4. Exchange Transfusion, Whole Blood [*adverse effects]; 5. Heart Arrest [etiology]; 6. Hypocalcemia [etiology, *prevention & control]; 7. Hypoglycemia [etiology]; | Provide MESH terms for the study
Prophylactic intravenous calcium therapy for exchange blood transfusion in the newborn | You are a research assistant. Based on the question please provide appropriate answers |
1. Azacitidine [analogs & derivatives, therapeutic use]; 2. Benzoates [*therapeutic use]; 3. Blood Transfusion [statistics & numerical data]; 4. Decitabine; 5. Hemorrhage [chemically induced]; 6. Hydrazines [*therapeutic use]; 7. Lenalidomide; 8. Leukemia, Myeloid, Acute [etiology]; 9. Myelodysplastic Syndromes [*complications, mortality]; 10. Pyrazoles [*therapeutic use]; 11. Quality of Life; 12. Randomized Controlled Trials as Topic; 13. Receptors, Fc [*therapeutic use]; 14. Recombinant Fusion Proteins [*therapeutic use]; 15. Thalidomide [analogs & derivatives, therapeutic use]; 16. Thrombocytopenia [*drug therapy, etiology]; 17. Thrombopoietin [*therapeutic use]; | Provide MESH terms for the study
Thrombopoietin mimetics for patients with myelodysplastic syndromes | You are a research assistant. Based on the question please provide appropriate answers |
1. *Blood Transfusion; 2. Blood Coagulation Disorders [*complications]; 3. Hemorrhage [*prevention & control]; 4. Spinal Puncture [*adverse effects]; | Provide MESH terms for the study
Plasma transfusions prior to lumbar punctures and epidural catheters for people with abnormal coagulation | You are a research assistant. Based on the question please provide appropriate answers |
1. Coagulants [*therapeutic use]; 2. Factor VIIa [*therapeutic use]; 3. Hemarthrosis [*prevention & control]; 4. Hemophilia A [complications, *drug therapy]; 5. Hemophilia B [complications, *drug therapy]; 6. Prothrombin [*therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Recombinant Proteins [therapeutic use]; | Provide MESH terms for the study
Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors | You are a research assistant. Based on the question please provide appropriate answers |
1. Antineoplastic Agents [administration & dosage]; 2. Antineoplastic Combined Chemotherapy Protocols [administration & dosage, adverse effects, standards]; 3. Bleomycin [administration & dosage, adverse effects]; 4. Chemoradiotherapy [methods, standards]; 5. Dacarbazine [administration & dosage, adverse effects]; 6. Disease-Free Survival; 7. Doxorubicin [administration & dosage, adverse effects]; 8. Hodgkin Disease [*drug therapy, *radiotherapy]; 9. Leukemia, Radiation-Induced [mortality, prevention & control]; 10. Myelodysplastic Syndromes [etiology]; 11. Neoplasms, Second Primary [etiology, mortality, *prevention & control]; 12. Radiotherapy [adverse effects, standards]; 13. Radiotherapy Dosage; 14. Randomized Controlled Trials as Topic; 15. Vinblastine [administration & dosage, adverse effects]; | Provide MESH terms for the study
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression‐free survival: individual participant data analysis | You are a research assistant. Based on the question please provide appropriate answers |
1. Administration, Oral; 2. Benzoates [administration & dosage, adverse effects, *therapeutic use]; 3. Clinical Trials, Phase II as Topic; 4. Clinical Trials, Phase III as Topic; 5. Deferasirox; 6. Deferiprone; 7. Deferoxamine [administration & dosage, therapeutic use]; 8. Erythrocyte Transfusion [adverse effects]; 9. Ferritins [blood]; 10. Iron Chelating Agents [administration & dosage, adverse effects, *therapeutic use]; 11. Iron Overload [blood, *drug therapy, etiology]; 12. Patient Satisfaction; 13. Pyridones [administration & dosage, therapeutic use]; 14. Randomized Controlled Trials as Topic; 15. Thalassemia [*complications, mortality, therapy]; 16. Triazoles [administration & dosage, adverse effects, *therapeutic use]; | Provide MESH terms for the study
Deferasirox for managing iron overload in people with thalassaemia | You are a research assistant. Based on the question please provide appropriate answers |
1. Acute Pain [etiology, *therapy]; 2. Anemia, Sickle Cell [complications, *therapy]; 3. *Fluid Therapy; 4. Pain Management [*methods]; | Provide MESH terms for the study
Fluid replacement therapy for acute episodes of pain in people with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Antisepsis [*methods]; 2. Blood Platelets [*microbiology]; 3. Disease Transmission, Infectious [*prevention & control]; 4. Furocoumarins; 5. Hemorrhage [epidemiology, *prevention & control]; 6. Photosensitizing Agents; 7. *Platelet Transfusion; 8. Randomized Controlled Trials as Topic; 9. Riboflavin; 10. Thrombocytopenia [*therapy]; 11. Ultraviolet Rays; | Provide MESH terms for the study
Pathogen‐reduced platelets for the prevention of bleeding | You are a research assistant. Based on the question please provide appropriate answers |
1. Antineoplastic Combined Chemotherapy Protocols [administration & dosage, adverse effects, *therapeutic use]; 2. Bleomycin [administration & dosage, adverse effects]; 3. Cyclophosphamide [administration & dosage, adverse effects]; 4. Dacarbazine [administration & dosage, adverse effects]; 5. Disease Progression; 6. Doxorubicin [administration & dosage, adverse effects]; 7. Etoposide [administration & dosage, adverse effects]; 8. Hodgkin Disease [*drug therapy, mortality, pathology]; 9. Prednisone [administration & dosage, adverse effects]; 10. Procarbazine [administration & dosage, adverse effects]; 11. Randomized Controlled Trials as Topic; 12. Vinblastine [administration & dosage, adverse effects]; 13. Vincristine [administration & dosage, adverse effects]; | Provide MESH terms for the study
Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma | You are a research assistant. Based on the question please provide appropriate answers |
1. Chemoradiotherapy; 2. Combined Modality Therapy [methods]; 3. Disease Progression; 4. Heart Diseases [mortality]; 5. Hodgkin Disease [*drug therapy, mortality, pathology, *radiotherapy]; 6. Infections [mortality]; 7. Neoplasms, Second Primary [mortality]; 8. Randomized Controlled Trials as Topic; 9. Recurrence; 10. Survival Analysis; | Provide MESH terms for the study
Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma | You are a research assistant. Based on the question please provide appropriate answers |
1. Anticoagulants [*administration & dosage, adverse effects]; 2. Heparin [*administration & dosage, adverse effects]; 3. Heparin, Low-Molecular-Weight [*administration & dosage, adverse effects]; 4. Numbers Needed To Treat; 5. Postoperative Complications [chemically induced, *prevention & control]; 6. Randomized Controlled Trials as Topic; 7. Surgical Procedures, Operative [statistics & numerical data]; 8. Thrombocytopenia [chemically induced, complications, *prevention & control]; 9. Thrombosis [etiology, *prevention & control]; 10. Venous Thrombosis [etiology, prevention & control]; | Provide MESH terms for the study
Unfractionated heparin versus low molecular weight heparins for avoiding heparin‐induced thrombocytopenia in postoperative patients | You are a research assistant. Based on the question please provide appropriate answers |
1. Exercise Therapy [*methods]; 2. Hemarthrosis [rehabilitation]; 3. Hemophilia A [*rehabilitation]; 4. Hemophilia B [*rehabilitation]; 5. Hydrotherapy; 6. Muscle Strength; 7. Muscle Stretching Exercises; 8. Pain [rehabilitation]; 9. Pain Measurement; 10. Randomized Controlled Trials as Topic; 11. Range of Motion, Articular; 12. Resistance Training; | Provide MESH terms for the study
Exercise for haemophilia | You are a research assistant. Based on the question please provide appropriate answers |
1. Acute Disease; 2. Anemia, Sickle Cell [*complications]; 3. Anti-Bacterial Agents [*therapeutic use]; 4. Community-Acquired Infections [drug therapy]; 5. Pneumonia, Bacterial [*drug therapy]; | Provide MESH terms for the study
Antibiotics for treating community‐acquired pneumonia in people with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. beta-Thalassemia [blood, *drug therapy]; 2. Blood Transfusion [*statistics & numerical data]; 3. Hematinics [*administration & dosage]; 4. Hemoglobin A [analysis]; 5. Hydroxyurea [*administration & dosage]; 6. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias | You are a research assistant. Based on the question please provide appropriate answers |
1. Benzoates [*therapeutic use]; 2. Bone Marrow Diseases [*complications]; 3. Chronic Disease; 4. Deamino Arginine Vasopressin [*therapeutic use]; 5. Hemorrhage [etiology, *prevention & control]; 6. Hemostatics [*therapeutic use]; 7. Hydrazines [*therapeutic use]; 8. Platelet Transfusion; 9. Pyrazoles [*therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Receptors, Fc [*therapeutic use]; 12. Recombinant Fusion Proteins [*therapeutic use]; 13. Thrombocytopenia [*complications]; 14. Thrombopoietin [*therapeutic use]; 15. Tranexamic Acid [*therapeutic use]; | Provide MESH terms for the study
Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta‐analysis and systematic review | You are a research assistant. Based on the question please provide appropriate answers |
1. Administration, Oral; 2. Bone Density [drug effects]; 3. Bone Density Conservation Agents [administration & dosage, *therapeutic use]; 4. Diphosphonates [administration & dosage, *therapeutic use]; 5. Fractures, Bone [*prevention & control]; 6. Injections, Intravenous; 7. Osteogenesis Imperfecta [*drug therapy]; 8. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Bisphosphonate therapy for osteogenesis imperfecta | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Sickle Cell [*complications]; 2. Caregivers [*education]; 3. *Health Knowledge, Attitudes, Practice; 4. *Patient Education as Topic; 5. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Interventions for patients and caregivers to improve knowledge of sickle cell disease and recognition of its related complications | You are a research assistant. Based on the question please provide appropriate answers |
1. Antineoplastic Agents [*therapeutic use]; 2. Bortezomib [*therapeutic use]; 3. Multiple Myeloma [*drug therapy]; 4. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Bortezomib for the treatment of multiple myeloma | You are a research assistant. Based on the question please provide appropriate answers |
1. Aminocaproic Acid [*therapeutic use]; 2. Antifibrinolytic Agents [*therapeutic use]; 3. Erythrocyte Transfusion [statistics & numerical data]; 4. Hematologic Diseases [*complications, drug therapy]; 5. Hemorrhage [etiology, *prevention & control]; 6. Lysine [analogs & derivatives]; 7. Platelet Transfusion [adverse effects]; 8. Thrombocytopenia [etiology, therapy]; 9. Thromboembolism; 10. Tranexamic Acid [*therapeutic use]; | Provide MESH terms for the study
Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders | You are a research assistant. Based on the question please provide appropriate answers |
1. Africa, Eastern; 2. Antimalarials [*economics, *supply & distribution, therapeutic use]; 3. Artemisinins [*economics, *supply & distribution, therapeutic use]; 4. *Drug Costs; 5. Financial Support; 6. Malaria [*drug therapy]; 7. Private Sector [*economics]; 8. Program Evaluation; 9. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Subsidising artemisinin‐based combination therapy in the private retail sector | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Iron-Deficiency [etiology, *prevention & control]; 2. Antimalarials [administration & dosage]; 3. Dietary Supplements [adverse effects]; 4. *Endemic Diseases; 5. Folic Acid [adverse effects]; 6. Iron [*administration & dosage, adverse effects]; 7. Malaria [chemically induced, *complications]; 8. Parasitemia [chemically induced, complications]; 9. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Oral iron supplements for children in malaria‐endemic areas | You are a research assistant. Based on the question please provide appropriate answers |
1. Erythropoietin [therapeutic use]; 2. Granulocyte-Macrophage Colony-Stimulating Factor [*therapeutic use]; 3. Macrophage Colony-Stimulating Factor [*therapeutic use]; 4. Myelodysplastic Syndromes [*drug therapy]; 5. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Sickle Cell [complications, *drug therapy]; 2. Antisickling Agents [*therapeutic use]; 3. Pain [*drug therapy]; 4. Piracetam [*therapeutic use]; 5. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Piracetam for reducing the incidence of painful sickle cell disease crises | You are a research assistant. Based on the question please provide appropriate answers |
1. Acute Disease; 2. Depression [therapy]; 3. Hematologic Neoplasms [*psychology]; 4. Leukemia [psychology]; 5. Meditation [*psychology]; 6. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Meditation for adults with haematological malignancies | You are a research assistant. Based on the question please provide appropriate answers |
1. *Erythrocyte Transfusion [adverse effects, methods, mortality]; 2. *Erythrocytes; 3. *Sodium Chloride; 4. Blood Specimen Collection [*methods]; 5. Infant, Extremely Premature; 6. Infant, Very Low Birth Weight; 7. Intensive Care Units, Neonatal [statistics & numerical data]; 8. Length of Stay [statistics & numerical data]; 9. Randomized Controlled Trials as Topic; 10. Respiration, Artificial [statistics & numerical data]; 11. Time Factors; | Provide MESH terms for the study
Washed versus unwashed red blood cells for transfusion for the prevention of morbidity and mortality in preterm infants | You are a research assistant. Based on the question please provide appropriate answers |
1. Antibodies, Monoclonal [*therapeutic use]; 2. Lymphoma [*drug therapy]; | Provide MESH terms for the study
Antibody therapies for lymphoma in children | You are a research assistant. Based on the question please provide appropriate answers |
1. *Antibiotic Prophylaxis; 2. Antineoplastic Combined Chemotherapy Protocols [adverse effects]; 3. Breast Neoplasms [drug therapy]; 4. Febrile Neutropenia [prevention & control]; 5. Fever [prevention & control]; 6. Granulocyte Colony-Stimulating Factor [*therapeutic use]; 7. Granulocyte-Macrophage Colony-Stimulating Factor [*therapeutic use]; 8. Infection Control [methods]; 9. Lung Neoplasms [drug therapy]; 10. Neoplasms [drug therapy, mortality]; 11. Randomized Controlled Trials as Topic; 12. Small Cell Lung Carcinoma [drug therapy]; | Provide MESH terms for the study
Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Sickle Cell [*complications]; 2. Anticoagulants [*therapeutic use]; 3. Dalteparin [*therapeutic use]; 4. Heparin, Low-Molecular-Weight [*therapeutic use]; 5. Pain Measurement; 6. Peripheral Vascular Diseases [*drug therapy, etiology]; 7. Randomized Controlled Trials as Topic; 8. Tinzaparin; | Provide MESH terms for the study
Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Acute Disease; 2. Blood Coagulation Factors [*therapeutic use]; 3. Factor VIII [immunology, therapeutic use]; 4. Factor VIIa [*therapeutic use]; 5. Hemophilia A [blood, *drug therapy]; 6. Hemophilia B [blood, *drug therapy]; 7. Hemorrhage [*drug therapy]; 8. Randomized Controlled Trials as Topic; 9. Recombinant Proteins [therapeutic use]; | Provide MESH terms for the study
Recombinant factor VIIa concentrate versus plasma‐derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors | You are a research assistant. Based on the question please provide appropriate answers |
1. *Central Venous Catheters; 2. Chronic Disease; 3. Hemorrhage [prevention & control]; 4. Liver Cirrhosis; 5. Platelet Count; 6. *Platelet Transfusion; 7. Randomized Controlled Trials as Topic; 8. Thrombocytopenia [blood, *therapy]; | Provide MESH terms for the study
Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia | You are a research assistant. Based on the question please provide appropriate answers |
1. Antineoplastic Agents [adverse effects]; 2. Bone Marrow Diseases [chemically induced]; 3. Hematologic Diseases [chemically induced, *complications]; 4. Hemorrhage [*prevention & control]; 5. Platelet Count [*standards]; 6. *Platelet Transfusion; 7. Randomized Controlled Trials as Topic; 8. Stem Cell Transplantation [*adverse effects]; 9. Thrombocytopenia [etiology, *therapy]; | Provide MESH terms for the study
Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation | You are a research assistant. Based on the question please provide appropriate answers |
1. Antineoplastic Agents [*therapeutic use]; 2. Disease-Free Survival; 3. Induction Chemotherapy [methods]; 4. Interleukin-2 [*therapeutic use]; 5. Leukemia, Myeloid, Acute [*drug therapy, mortality]; 6. Maintenance Chemotherapy [*methods, mortality]; 7. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission | You are a research assistant. Based on the question please provide appropriate answers |
1. Cause of Death; 2. Hematologic Neoplasms [*therapy]; 3. Hematopoietic Stem Cell Transplantation [*adverse effects]; 4. Hemorrhage [etiology, *prevention & control]; 5. Platelet Transfusion [*methods]; 6. Randomized Controlled Trials as Topic; 7. Stem Cell Transplantation [*adverse effects]; 8. Thrombocytopenia [chemically induced, *complications, therapy]; 9. Time Factors; | Provide MESH terms for the study
Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation | You are a research assistant. Based on the question please provide appropriate answers |
1. Benzylamines; 2. Cyclams; 3. Early Termination of Clinical Trials; 4. Granulocyte Colony-Stimulating Factor [*pharmacology]; 5. Hematopoietic Stem Cell Mobilization [*methods]; 6. Hematopoietic Stem Cell Transplantation; 7. Heterocyclic Compounds [*pharmacology]; 8. Lymphoma [therapy]; 9. Lymphoma, Non-Hodgkin [mortality, *therapy]; 10. Multiple Myeloma [mortality, *therapy]; 11. Randomized Controlled Trials as Topic; 12. Time Factors; 13. Transplantation, Autologous; | Provide MESH terms for the study
Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Aplastic [therapy]; 2. Anemia, Refractory [therapy]; 3. Bone Marrow Diseases [*therapy]; 4. Clinical Protocols; 5. Erythrocyte Transfusion [*methods]; 6. Leukemia, Myelomonocytic, Chronic [therapy]; 7. Myelodysplastic Syndromes [therapy]; 8. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders | You are a research assistant. Based on the question please provide appropriate answers |
1. Cause of Death; 2. Hematologic Diseases [*therapy]; 3. Hemorrhage [*prevention & control, *therapy]; 4. Platelet Transfusion [adverse effects, *methods, statistics & numerical data]; 5. Randomized Controlled Trials as Topic; 6. *Stem Cell Transplantation; 7. Thrombocytopenia [complications, *therapy]; 8. Time Factors; | Provide MESH terms for the study
A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation | You are a research assistant. Based on the question please provide appropriate answers |
1. Anthracyclines [*therapeutic use]; 2. Antibiotics, Antineoplastic [*therapeutic use]; 3. Daunorubicin [analogs & derivatives, therapeutic use]; 4. Doxorubicin [therapeutic use]; 5. Idarubicin [*therapeutic use]; 6. Induction Chemotherapy [*methods]; 7. Leukemia, Myeloid, Acute [*drug therapy]; 8. Mitoxantrone [therapeutic use]; 9. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia | You are a research assistant. Based on the question please provide appropriate answers |
1. Antithrombin III [therapeutic use]; 2. Cause of Death; 3. Cholagogues and Choleretics [*therapeutic use]; 4. Glutamine [therapeutic use]; 5. Hematopoietic Stem Cell Transplantation [*adverse effects]; 6. Heparin, Low‐Molecular‐Weight [therapeutic use]; 7. Hepatic Veno‐Occlusive Disease [mortality, *prevention & control]; 8. Plasma; 9. Polydeoxyribonucleotides [therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Ursodeoxycholic Acid [*therapeutic use]; | Provide MESH terms for the study
Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell transplantation | You are a research assistant. Based on the question please provide appropriate answers |
1. *Adaptation, Psychological; 2. Depression [psychology, therapy]; 3. Hemoglobin SC Disease [*therapy]; 4. Outcome Assessment, Health Care; 5. Pain [psychology]; 6. Pain Management [*methods]; 7. Psychotherapy [*methods]; 8. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Psychological therapies for sickle cell disease and pain | You are a research assistant. Based on the question please provide appropriate answers |
1. Janus Kinase 1 [*antagonists & inhibitors]; 2. Janus Kinase 2 [*antagonists & inhibitors]; 3. Nitriles; 4. Primary Myelofibrosis [*drug therapy, mortality]; 5. Protein Kinase Inhibitors [*therapeutic use]; 6. Pyrazoles [*therapeutic use]; 7. Pyrimidines; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis | You are a research assistant. Based on the question please provide appropriate answers |
1. Biopterin [administration & dosage, adverse effects, *analogs & derivatives]; 2. Phenylalanine [*blood]; 3. Phenylketonurias [blood, *drug therapy]; 4. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Sapropterin dihydrochloride for phenylketonuria | You are a research assistant. Based on the question please provide appropriate answers |
1. 1‐Deoxynojirimycin [adverse effects, analogs & derivatives]; 2. Enzyme Inhibitors [adverse effects]; 3. Enzyme Replacement Therapy [*methods]; 4. Gaucher Disease [blood, *drug therapy]; 5. Glucosylceramidase [therapeutic use]; 6. Hemoglobin A [metabolism]; 7. Hepatomegaly [drug therapy]; 8. Platelet Count; 9. Randomized Controlled Trials as Topic; 10. Splenomegaly [drug therapy]; 11. Substrate Specificity; | Provide MESH terms for the study
Enzyme replacement and substrate reduction therapy for Gaucher disease | You are a research assistant. Based on the question please provide appropriate answers |
1. *Food, Formulated; 2. Dietary Proteins [*administration & dosage]; 3. Phenylalanine [*blood]; 4. Phenylalanine Hydroxylase [deficiency]; 5. Phenylketonurias [diet therapy, *therapy]; 6. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Protein substitute for children and adults with phenylketonuria | You are a research assistant. Based on the question please provide appropriate answers |
1. Antimalarials [*therapeutic use]; 2. Artemether, Lumefantrine Drug Combination; 3. Artemisinins [*therapeutic use]; 4. Drug Combinations; 5. Ethanolamines [therapeutic use]; 6. Fluorenes [therapeutic use]; 7. Malaria, Falciparum [*drug therapy]; 8. Naphthoquinones [*therapeutic use]; 9. Quinolines [therapeutic use]; 10. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Artemisinin‐naphthoquine for treating uncomplicated Plasmodium falciparum malaria | You are a research assistant. Based on the question please provide appropriate answers |
1. *Surgical Procedures, Operative; 2. *Tooth Extraction; 3. Aminocaproic Acid [therapeutic use]; 4. Antifibrinolytic Agents [*therapeutic use]; 5. Blood Loss, Surgical [*prevention & control]; 6. Factor VIIa [therapeutic use]; 7. Hemophilia A [*drug therapy]; 8. Hemophilia B [*drug therapy]; 9. Hemostasis, Surgical [*methods]; 10. Randomized Controlled Trials as Topic; 11. Recombinant Proteins [therapeutic use]; 12. Tranexamic Acid [therapeutic use]; | Provide MESH terms for the study
Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery | You are a research assistant. Based on the question please provide appropriate answers |
1. *Positron‐Emission Tomography [methods]; 2. Antineoplastic Agents [therapeutic use]; 3. Chemoradiotherapy [methods]; 4. Disease‐Free Survival; 5. Fluorodeoxyglucose F18; 6. Hodgkin Disease [*diagnostic imaging, mortality, pathology, *therapy]; 7. Radiopharmaceuticals; 8. Randomized Controlled Trials as Topic; 9. Selection Bias; | Provide MESH terms for the study
Positron emission tomography‐adapted therapy for first‐line treatment in individuals with Hodgkin lymphoma | You are a research assistant. Based on the question please provide appropriate answers |
1. Antibodies, Monoclonal, Humanized [*therapeutic use]; 2. Clinical Trials, Phase III as Topic; 3. Hemoglobinuria, Paroxysmal [*drug therapy]; 4. Multicenter Studies as Topic; 5. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria | You are a research assistant. Based on the question please provide appropriate answers |
1. Benzoates [*therapeutic use]; 2. Chelation Therapy [*methods]; 3. Deferasirox; 4. Iron Chelating Agents [*therapeutic use]; 5. Iron Overload [*drug therapy]; 6. Myelodysplastic Syndromes [*complications]; 7. Triazoles [*therapeutic use]; | Provide MESH terms for the study
Deferasirox for managing iron overload in people with myelodysplastic syndrome | You are a research assistant. Based on the question please provide appropriate answers |
1. Antimalarials [*therapeutic use]; 2. Malaria [drug therapy, *prevention & control]; 3. Mosquito Control; 4. Pregnancy Complications, Parasitic [drug therapy, *prevention & control]; 5. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment | You are a research assistant. Based on the question please provide appropriate answers |
1. Factor VIII; 2. Hemophilia A [complications, *drug therapy]; 3. Hemorrhage [*drug therapy, etiology]; | Provide MESH terms for the study
Interventions for treating acute bleeding episodes in people with acquired hemophilia A | You are a research assistant. Based on the question please provide appropriate answers |
1. Allografts; 2. Calcineurin Inhibitors; 3. Cyclosporine [therapeutic use]; 4. Graft vs Host Disease [mortality, *prevention & control]; 5. Hematopoietic Stem Cell Transplantation [*adverse effects]; 6. Immunosuppressive Agents [adverse effects, *therapeutic use]; 7. Methotrexate [adverse effects, *therapeutic use]; 8. Mycophenolic Acid [adverse effects, *analogs & derivatives, therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Recurrence; 11. Tacrolimus [therapeutic use]; | Provide MESH terms for the study
Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving allogeneic hematopoietic stem cell transplantation | You are a research assistant. Based on the question please provide appropriate answers |
1. Antimetabolites, Antineoplastic [therapeutic use]; 2. Central Nervous System Neoplasms [drug therapy, *radiotherapy]; 3. Combined Modality Therapy [methods]; 4. Cranial Irradiation [*methods]; 5. Cytarabine [therapeutic use]; 6. Early Termination of Clinical Trials; 7. Lymphoma [drug therapy, *radiotherapy]; 8. Methotrexate [therapeutic use]; 9. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
The role of additional radiotherapy for primary central nervous system lymphoma | You are a research assistant. Based on the question please provide appropriate answers |
1. Anemia, Sickle Cell [blood, *therapy]; 2. Benzoates [adverse effects, *therapeutic use]; 3. Chelation Therapy [adverse effects, *methods]; 4. Deferasirox; 5. Deferoxamine [adverse effects, therapeutic use]; 6. Erythrocyte Transfusion [adverse effects]; 7. Ferritins [blood]; 8. Iron Chelating Agents [adverse effects, *therapeutic use]; 9. Iron Overload [*drug therapy, etiology]; 10. Randomized Controlled Trials as Topic; 11. Triazoles [adverse effects, *therapeutic use]; | Provide MESH terms for the study
Deferasirox for managing transfusional iron overload in people with sickle cell disease | You are a research assistant. Based on the question please provide appropriate answers |
1. Antimalarials [*therapeutic use]; 2. Artemether, Lumefantrine Drug Combination; 3. Artemisinins [*therapeutic use]; 4. Artesunate; 5. Drug Combinations; 6. Drug Therapy, Combination [methods]; 7. Ethanolamines [therapeutic use]; 8. Fluorenes [therapeutic use]; 9. Malaria, Falciparum [*drug therapy]; 10. Mefloquine [therapeutic use]; 11. Parasitemia [drug therapy]; 12. Quinolines [*therapeutic use]; 13. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Dihydroartemisinin‐piperaquine for treating uncomplicated Plasmodium falciparum malaria | You are a research assistant. Based on the question please provide appropriate answers |
1. Antimalarials [*administration & dosage]; 2. Chloroquine [administration & dosage]; 3. Drug Administration Schedule; 4. Malaria, Vivax [*prevention & control]; 5. Plasmodium vivax; 6. Primaquine [*administration & dosage]; 7. Randomized Controlled Trials as Topic; 8. Secondary Prevention; | Provide MESH terms for the study
Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine | You are a research assistant. Based on the question please provide appropriate answers |
1. Antimalarials [*therapeutic use]; 2. Artemether, Lumefantrine Drug Combination; 3. Artemisinins [*therapeutic use]; 4. Drug Combinations; 5. Drug Resistance; 6. Drug Therapy, Combination [methods]; 7. Ethanolamines [therapeutic use]; 8. Fluorenes [therapeutic use]; 9. Malaria, Vivax [*drug therapy, prevention & control]; 10. Parasitemia [*drug therapy]; 11. Primaquine [therapeutic use]; 12. Pyrimethamine [therapeutic use]; 13. Quinolines [therapeutic use]; 14. Randomized Controlled Trials as Topic; 15. Secondary Prevention; 16. Sulfadoxine [therapeutic use]; | Provide MESH terms for the study
Artemisinin‐based combination therapy for treating uncomplicated Plasmodium vivax malaria | You are a research assistant. Based on the question please provide appropriate answers |
1. Immunotherapy; 2. Mouth; 3. Neck; 4. *Neoplasm Recurrence, Local; 5. *Oropharyngeal Neoplasms [surgery]; 6. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment | You are a research assistant. Based on the question please provide appropriate answers |
1. *Barotrauma [therapy]; 2. Disease Progression; 3. *Hyperbaric Oxygenation [methods]; 4. *Neoplasms [therapy]; 5. *Osteoradionecrosis [prevention & control]; 6. Pain; 7. *Radiation Injuries [prevention & control]; | Provide MESH terms for the study
Hyperbaric oxygen therapy for late radiation tissue injury | You are a research assistant. Based on the question please provide appropriate answers |
1. Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; 2. Carboplatin [therapeutic use]; 3. *Carcinoma, Non-Small-Cell Lung [drug therapy, genetics]; 4. Cisplatin; 5. *Lung Neoplasms [drug therapy, genetics]; 6. Mutation; | Provide MESH terms for the study
Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status | You are a research assistant. Based on the question please provide appropriate answers |
1. *Antineoplastic Agents [adverse effects]; 2. Carcinoma, Ovarian Epithelial [drug therapy]; 3. *Ovarian Neoplasms [drug therapy]; 4. Randomized Controlled Trials as Topic; 5. Recurrence; 6. Systematic Reviews as Topic; | Provide MESH terms for the study
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Abdominal Pain; 2. Combined Modality Therapy; 3. *Neoadjuvant Therapy; 4. Neoplasm Recurrence, Local [epidemiology]; 5. *Rectal Neoplasms [surgery]; | Provide MESH terms for the study
Local versus radical surgery for early rectal cancer with or without neoadjuvant or adjuvant therapy | You are a research assistant. Based on the question please provide appropriate answers |
1. *Colorectal Neoplasms [surgery]; 2. *Digestive System Surgical Procedures; 3. Postoperative Complications [prevention & control]; 4. Preoperative Exercise; 5. Quality of Life; | Provide MESH terms for the study
Prehabilitation versus no prehabilitation to improve functional capacity, reduce postoperative complications and improve quality of life in colorectal cancer surgery | You are a research assistant. Based on the question please provide appropriate answers |
1. Axitinib; 2. *Carcinoma, Renal Cell [drug therapy]; 3. Network Meta-Analysis; 4. Nivolumab; 5. Sunitinib; | Provide MESH terms for the study
First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis | You are a research assistant. Based on the question please provide appropriate answers |
1. *Angiogenesis Inhibitors [adverse effects]; 2. Bevacizumab [adverse effects]; 3. Carcinoma, Ovarian Epithelial [drug therapy]; 4. Neoplasm Recurrence, Local [chemically induced, drug therapy]; 5. *Ovarian Neoplasms [drug therapy]; 6. Vascular Endothelial Growth Factor A; | Provide MESH terms for the study
Angiogenesis inhibitors for the treatment of epithelial ovarian cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. *Breast Neoplasms [diagnostic imaging]; 2. Early Detection of Cancer; 3. Mammography; 4. Randomized Controlled Trials as Topic; 5. *Ultrasonography, Mammary; | Provide MESH terms for the study
Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk | You are a research assistant. Based on the question please provide appropriate answers |
1. *COVID-19 [complications]; 2. *Endometrial Neoplasms [therapy]; 3. Obesity [complications, therapy]; 4. Overweight [complications, therapy]; 5. Weight Loss; | Provide MESH terms for the study
Interventions for weight reduction in obesity to improve survival in women with endometrial cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. *Breast Neoplasms [surgery]; 2. *Carcinoma, Intraductal, Noninfiltrating [etiology, surgery]; 3. *Mammaplasty [adverse effects]; 4. Mastectomy [adverse effects, methods]; 5. Necrosis; | Provide MESH terms for the study
Skin‐sparing mastectomy for the treatment of breast cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. *Exercise; 2. Exercise Therapy [adverse effects]; 3. Fatigue [etiology, therapy]; 4. *Neoplasms [complications, radiotherapy]; 5. Quality of Life; 6. Walk Test; 7. Walking; | Provide MESH terms for the study
Exercise interventions for adults with cancer receiving radiation therapy alone | You are a research assistant. Based on the question please provide appropriate answers |
1. Prostatectomy [adverse effects]; 2. *Prostatic Neoplasms [pathology]; 3. Systematic Reviews as Topic; | Provide MESH terms for the study
Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Anastomotic Leak [drug therapy, prevention & control]; 2. *Anti-Bacterial Agents [administration & dosage, therapeutic use]; 3. *Colorectal Surgery [adverse effects]; 4. *Ileus [drug therapy, prevention & control]; 5. Preoperative Care; 6. *Surgical Wound Infection [drug therapy, prevention & control]; | Provide MESH terms for the study
Preoperative combined mechanical and oral antibiotic bowel preparation for preventing complications in elective colorectal surgery | You are a research assistant. Based on the question please provide appropriate answers |
1. Adrenal Cortex Hormones [adverse effects]; 2. Dexamethasone [adverse effects]; 3. Fatigue [drug therapy, etiology]; 4. Modafinil; 5. *Neoplasms [complications, drug therapy]; 6. *Quality of Life; | Provide MESH terms for the study
Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. *Antineoplastic Agents [adverse effects]; 2. Ipilimumab; 3. *Melanoma [drug therapy, pathology]; 4. Melanoma, Cutaneous Malignant; 5. Neoplasm Staging; 6. Nivolumab; 7. Randomized Controlled Trials as Topic; 8. *Skin Neoplasms [drug therapy, pathology]; | Provide MESH terms for the study
Neoadjuvant treatment for stage III and IV cutaneous melanoma | You are a research assistant. Based on the question please provide appropriate answers |
1. *Agaricales; 2. *Colorectal Neoplasms [drug therapy, radiotherapy]; 3. *Drug-Related Side Effects and Adverse Reactions; 4. Nausea; 5. *Neutropenia; 6. Randomized Controlled Trials as Topic; 7. Trametes; | Provide MESH terms for the study
Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. *Antifungal Agents [adverse effects]; 2. *Febrile Neutropenia [chemically induced, prevention & control]; 3. Invasive Fungal Infections [drug therapy, prevention & control]; 4. *Neoplasms [drug therapy]; 5. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. *Brain Neoplasms; 2. Cognition; 3. *Cognitive Dysfunction [etiology, prevention & control]; 4. Cranial Irradiation [adverse effects]; 5. *Dementia; 6. Donepezil; 7. Fatigue [etiology, prevention & control]; 8. Memantine; 9. *Methylphenidate [therapeutic use]; 10. Modafinil [therapeutic use]; 11. Quality of Life; | Provide MESH terms for the study
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation | You are a research assistant. Based on the question please provide appropriate answers |
1. *Carcinoma, Non-Small-Cell Lung [surgery]; 2. Dyspnea; 3. Fatigue; 4. Forced Expiratory Volume; 5. *Lung Neoplasms [surgery]; 6. Postoperative Complications [epidemiology]; | Provide MESH terms for the study
Preoperative exercise training for people with non‐small cell lung cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Anthracyclines [adverse effects]; 2. Antibiotics, Antineoplastic [adverse effects]; 3. Cardiotonic Agents [therapeutic use]; 4. Cardiotoxicity [drug therapy, etiology, prevention & control]; 5. *Dexrazoxane [therapeutic use]; 6. *Heart Failure [drug therapy]; 7. *Leukemia, Myeloid, Acute [drug therapy]; 8. *Polyketides [therapeutic use]; 9. Systematic Reviews as Topic; | Provide MESH terms for the study
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines | You are a research assistant. Based on the question please provide appropriate answers |
1. Chemoradiotherapy [methods]; 2. Cytoreduction Surgical Procedures; 3. Hysterectomy [methods]; 4. Neoplasm Staging; 5. Neoplasm, Residual; 6. *Uterine Cervical Neoplasms [pathology, therapy]; | Provide MESH terms for the study
Debulking hysterectomy followed by chemoradiotherapy versus chemoradiotherapy for FIGO stage (2019) IB3/II cervical cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Analgesics, Opioid [adverse effects]; 2. Naloxone; 3. Naltrexone [analogs & derivatives]; 4. Narcotic Antagonists [adverse effects]; 5. *Neoplasms [drug therapy]; 6. *Opioid-Induced Constipation; 7. Oxycodone; 8. Palliative Care; 9. Quaternary Ammonium Compounds; 10. *Substance Withdrawal Syndrome; | Provide MESH terms for the study
Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care | You are a research assistant. Based on the question please provide appropriate answers |
1. *Carcinoma, Ovarian Epithelial [pathology, surgery]; 2. Controlled Clinical Trials as Topic; 3. *Cytoreduction Surgical Procedures; 4. Disease Progression; 5. Observational Studies as Topic; 6. *Ovarian Neoplasms [pathology, surgery]; 7. Treatment Outcome; | Provide MESH terms for the study
Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Chemoradiotherapy [adverse effects, methods]; 2. Chemotherapy, Adjuvant [methods]; 3. Hysterectomy; 4. Neoadjuvant Therapy [methods]; 5. *Uterine Cervical Neoplasms [drug therapy, radiotherapy]; | Provide MESH terms for the study
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Bias; 2. *Early Detection of Cancer [methods]; 3. *Lung Neoplasms [diagnostic imaging, mortality]; 4. Randomized Controlled Trials as Topic; 5. Tomography, X-Ray Computed [methods]; | Provide MESH terms for the study
Impact of low‐dose computed tomography (LDCT) screening on lung cancer‐related mortality | You are a research assistant. Based on the question please provide appropriate answers |
1. Alopecia [drug therapy]; 2. Bridged-Ring Compounds; 3. Carcinoma, Ovarian Epithelial [drug therapy]; 4. Neoplasm Recurrence, Local [drug therapy]; 5. *Neutropenia; 6. *Ovarian Neoplasms [drug therapy]; 7. Paclitaxel [adverse effects]; 8. Taxoids [adverse effects]; | Provide MESH terms for the study
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Analgesics, Opioid [adverse effects]; 2. *Cancer Pain [drug therapy]; 3. Constipation [chemically induced]; 4. Morphine [adverse effects]; 5. Nausea [chemically induced, drug therapy]; 6. *Neoplasms [complications, drug therapy]; 7. Oxycodone [adverse effects]; 8. Pain [drug therapy, etiology]; 9. Quality of Life; 10. Reproducibility of Results; 11. Sleepiness; 12. Vomiting [chemically induced]; | Provide MESH terms for the study
Oxycodone for cancer‐related pain | You are a research assistant. Based on the question please provide appropriate answers |
1. Length of Stay; 2. *Neoplasms; 3. Perioperative Care; 4. Postoperative Complications [epidemiology, prevention & control]; 5. Quality of Life; | Provide MESH terms for the study
Perioperative enhanced recovery programmes for women with gynaecological cancers | You are a research assistant. Based on the question please provide appropriate answers |
1. Carbon Dioxide [adverse effects]; 2. Helium [adverse effects]; 3. *Insufflation [adverse effects, methods]; 4. *Laparoscopy [adverse effects, methods]; 5. Nitrous Oxide [adverse effects]; 6. *Pneumoperitoneum [etiology]; | Provide MESH terms for the study
Gases for establishing pneumoperitoneum during laparoscopic abdominal surgery | You are a research assistant. Based on the question please provide appropriate answers |
1. Bevacizumab [therapeutic use]; 2. Carboplatin [adverse effects]; 3. Carcinoma, Ovarian Epithelial [drug therapy, surgery]; 4. *Ovarian Neoplasms [surgery]; 5. *Paclitaxel [adverse effects]; | Provide MESH terms for the study
Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Carcinoma, Ovarian Epithelial [drug therapy, surgery]; 2. Neoplasm Recurrence, Local [drug therapy]; 3. *Ovarian Neoplasms [drug therapy, genetics]; 4. *Poly(ADP-ribose) Polymerase Inhibitors [adverse effects]; 5. Poly(ADP-ribose) Polymerases [therapeutic use]; | Provide MESH terms for the study
Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Length of Stay; 2. *Pancreatectomy; 3. Pancreatic Fistula; 4. *Pancreaticoduodenectomy [adverse effects]; 5. Postoperative Complications; | Provide MESH terms for the study
Antecolic versus retrocolic reconstruction after partial pancreaticoduodenectomy | You are a research assistant. Based on the question please provide appropriate answers |
1. Aromatase Inhibitors [adverse effects]; 2. *Breast Neoplasms [drug therapy]; 3. *Musculoskeletal Pain [chemically induced, drug therapy, prevention & control]; 4. Quality of Life; 5. Tamoxifen [adverse effects]; | Provide MESH terms for the study
Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Anaplastic Lymphoma Kinase [genetics]; 2. *Carcinoma, Non-Small-Cell Lung [drug therapy, genetics]; 3. *Lung Neoplasms [drug therapy, genetics]; 4. Progression-Free Survival; 5. Protein Kinase Inhibitors [adverse effects]; | Provide MESH terms for the study
Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. *Brain Neoplasms [therapy]; 2. *Caregivers; 3. Exercise; 4. Palliative Care; 5. Quality of Life; | Provide MESH terms for the study
Early palliative interventions for improving outcomes in people with a primary malignant brain tumour and their carers | You are a research assistant. Based on the question please provide appropriate answers |
1. Chemoradiotherapy, Adjuvant; 2. *Mouth Neoplasms [drug therapy]; 3. Neoplasm Recurrence, Local; 4. *Oropharyngeal Neoplasms [drug therapy]; | Provide MESH terms for the study
Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy | You are a research assistant. Based on the question please provide appropriate answers |
1. *Abdomen [surgery]; 2. *Drainage; 3. Length of Stay; 4. Pancreas; 5. Pancreatic Fistula; | Provide MESH terms for the study
Prophylactic abdominal drainage for pancreatic surgery | You are a research assistant. Based on the question please provide appropriate answers |
1. *Carcinoma, Non-Small-Cell Lung [drug therapy]; 2. Chemoradiotherapy; 3. Immunotherapy; 4. *Lung Neoplasms [drug therapy]; 5. Progression-Free Survival; 6. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent | You are a research assistant. Based on the question please provide appropriate answers |
1. *Carcinoma, Transitional Cell [surgery]; 2. Cystectomy [adverse effects]; 3. Neoplasm Recurrence, Local; 4. *Urinary Bladder Neoplasms [surgery]; | Provide MESH terms for the study
Blue versus white light for transurethral resection of non‐muscle invasive bladder cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. *Antiemetics [therapeutic use]; 2. *Antineoplastic Agents [adverse effects]; 3. Nausea [chemically induced, drug therapy, prevention & control]; 4. Network Meta-Analysis; 5. Palonosetron [therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Vomiting [chemically induced, drug therapy, prevention & control]; | Provide MESH terms for the study
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta‐analysis | You are a research assistant. Based on the question please provide appropriate answers |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.